Managed Healthcare Executive February 19, 2024
MHE Staff

Amtagvi was approved to treat patients with advanced melanoma. It is a one-time cell therapy that will be administered at authorized treatment centers and have a wholesale acquisition cost of $515,000.

The FDA has granted accelerated approval for Amtagvi (lifileucel) to treat patients with advanced melanoma. Developed by Iovance Biotherapeutics, Amtagvi is the first approved tumor-infiltrating lymphocyte (TIL) therapy designed for patients with advanced melanoma who have experienced progression after previous treatment. It is indicated for those patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. Amtagvi is a one-time therapy that requires a patient’s cancer-fighting cells to be collected so...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns
HHS Explores Stronger FDA Oversight for Food Ingredients

Share This Article